Nurix Therapeutics Reports Strong Q3 Earnings and Revenue Growth
Nurix Therapeutics (NASDAQ:NRIX) reported strong financial results for the third quarter, with GAAP earnings per share of $4.73, exceeding estimates by $1.64. The company also generated revenue of $673.1 million in Q3, a significant increase from previous expectations and representing an 8,420% year-over-year growth. As of August 31, 2026, Nurix Therapeutics held cash, cash equivalents, and marketable securities totaling $1.1 billion, up sharply from $592.9 million as of November 30, 2025. This substantial increase in liquidity highlights the company's strong financial position following its recent performance. The results reflect a significant turnaround for Nurix Therapeutics, driven by robust revenue growth and improved profitability.
Tickers: $NRIX
Topics: Biotech Earnings Financial Performance
Read the full article at Seeking Alpha
Part of the story Goldman Sachs Reports Strong Q3 Earnings with Record Revenues Across Key Divisions (13 articles)